Plaque inhibition by guanidino propyl piperazine (CKO 569A).
The plaque inhibiting effect of the antibacterial substance, guanidino propyl piperazine (CKO 569A) has been analized in a clinical study of 10 adults. Plaque formation was enhanced by three daily rinses with 15% sucrose. Normal hygiene was performed. The effects of a twice daily mouthwash of 30 s duration with 0.2, 0.1 and 0.05% CKO 569A, 0.05% chlorhexidine and a placebo on plaque formation were compared through a registration of plaque scores. Each solution was tested over a period of 5 days. As a result of this study it could be concluded that in humans CKO 569A is an effective inhibitor of plaque, and that lingual plaque scores appear to be a good indicator of plaque inhibiting activity.
D000293:Adolescent; D000328:Adult; D055598:Chemical Phenomena; D002621:Chemistry; D002710:Chlorhexidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003773:Dental Plaque / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006146:Guanidines / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009910:Oral Hygiene / Q000379:methods; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D010919:Placebos; D011897:Random Allocation
D006146:Guanidines; D010879:Piperazines; D010919:Placebos; C026611:guanidino propyl piperazine; D002710:Chlorhexidine